Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Jeremy Warren Chief Executive Officer ADDRESS Minton Park London Road Amesbury Wiltshire SP4 7RT United Kingdom TELEPHONE +44 1 980 676 060 FAX +44 1 980 624 703 EMAIL admin@nanosight.com YEAR FOUNDED 2002 NanoSight www.nanosight.com FINANCIAL SUMMARY 2005 2006 2007 2008 2009 2010 2011 £k As filed As filed Audited Audited Audited Audited Audited Total Sales 243 247 472 820 1,610 2,249 3,775 Gross Profit 81 91 282 507 1008 1464 2417 Gross Margin 33% 37% 60% 62% 63% 65% 64% Total Overheads 291 473 510 748 1,368 1,446 1,861 PBT -210 -382 -228 -241 -360 18 556 Sales Growth Rate 2% 91% 74% 96% 40% 68% COMPANY PROFILE NanoSight’s unique role in potential early detection of cancer is developing rapidly. Our scientific focus continues to be the refinement of Nanoparticle Tracking Analysis. NTA is a unique methodology for detection and characterisation of nanoparticles in liquids. Applied to cell-derived biological nanoparticles (exosomes and microvesicles) it has emerging potential as a diagnostic platform for a Prostate, Oral, Liver and Gastric cancers, Diabetes, Pre-eclampsia, Parkinson’s disease, Autoimmune and Renal diseases. Our practical work is collaboration with research groups using our instruments to develop rigorous protocols for counting and speciation disease-specific exosomes. Recent publication of American Society for Testing Materials standard ASTM E2834 demonstrates our progress in refining NTA methodology. MANAGEMENT Dr Robert Carr, CTO & Founder Jeremy Warren, CEO John Knowles, Chairman & Founder t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Aaron Powers President Dave Reusswig Vice President ADDRESS 3820 Ohio Ave, Ste 8-14 St Charles, IL 60174 TELEPHONE 630-400-2135 FAX 480-287-8984 EMAIL aapowers@mac.com YEAR FOUNDED 2007 Northern Biotechnologies llc www.nothernbiotechnologies.com FINANCIAL SUMMARY Northern Biotechnologies has raised $1.5M in round “a” private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, antiviral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners. COMPANY PROFILE Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and antiviral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets. Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of “green probiotic” cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies. MANAGEMENT Aaron Powers, President Dave Reusswig, Vice President Katan & <strong>Associates</strong>, Financial Consultants t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69: CONTACT Tom Johnston Chief Executiv
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?